Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

PURPOSE: This phase I trial assessed the safety, maximally tolerated dose (MTD) and pharmacokinetics of TRKA/CDK inhibitor PHA-848125AC in adult patients with advanced/metastatic solid tumors. PATIENTS AND METHODS: Patients with relapsed or refractory solid tumors, for which no standard therapy exis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Weiss, Glen J., Hidalgo, Manuel, Borad, Mitesh J., Laheru, Daniel, Tibes, Raoul, Ramanathan, Ramesh K., Blaydorn, Lisa, Jameson, Gayle, Jimeno, Antonio, Isaacs, Jeffrey D., Scaburri, Angela, Pacciarini, Maria Adele, Fiorentini, Francesco, Ciomei, Marina, Von Hoff, Daniel D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3561458/
https://ncbi.nlm.nih.gov/pubmed/22160853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9774-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge